Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent

Published on 10/01/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 47.70 percent to USD 22.97 billion. Eli Lilly and Company stock costs EUR 1,015.60 on October 1, 2026 after EUR 1,027.70.

Aquarellmalerei eines CVD-Deposition-Tools in zarten Blau- und Silbertönen, ein Techniker steht an der Bedienkonsole — Lam Research US5324571083 Deposition Tool als zartes blaues Aquarell mit Techniker im hellen Reinraum, Illustration mit AI erstellt.

Eli Lilly and Company (ISIN US5324571083) was trading at EUR 1,015.60 at Lang & Schwarz on October 1, 2026 at 4:31 p.m. CEST, down 1.18 percent from EUR 1,027.70. On September 29, 2026, Eli Lilly and Company presented new Foundayo data showing 1.50 percent greater weight loss and 0.30 percent greater A1C reduction than oral semaglutide 25 mg at 52 weeks.

Foundayo adds evidence to Lilly portfolio

The comparison used data from ACHIEVE-3 and PIONEER PLUS rather than a direct head-to-head trial. Foundayo 17.2 mg is a once-daily oral treatment, giving Lilly a differentiated product format as the company expands its obesity and diabetes portfolio.

A separate September 29, 2026 Eli Lilly and Company analysis found that Zepbound 15 mg produced 4.50 percent greater weight loss than Wegovy HD at 72 weeks. In the underlying SURMOUNT-5 trial, Zepbound achieved 20.20 percent average weight reduction versus 13.70 percent for Wegovy.

Second-quarter growth sets the bar

For the second quarter of 2026, revenue reached USD 22.97 billion, up 47.70 percent year over year, while earnings per share were USD 8.38 versus a USD 6.40 consensus estimate, MarketBeat reported. The figures show why product launches and volume growth remain central to the valuation, while pricing pressure and the pace of oral GLP-1 adoption remain important execution variables.

The same MarketBeat report said JPMorgan raised its price target from USD 1,400.00 to USD 1,500.00 on September 28, 2026 and maintained an Overweight rating. The target is a USD 343.00 gap above the latest primary-exchange quote of USD 1,157.08 cited in the market data, but that comparison uses different venues and currencies from the euro reference price.

Stock falls below prior close

Eli Lilly and Company stock was trading at EUR 1,015.60 at Lang & Schwarz on October 1, 2026 at 4:31 p.m. CEST, down 1.18 percent versus the Lang & Schwarz prior close of EUR 1,027.70 dated September 30, 2026. On the NYSE, the primary-exchange quote was USD 1,145.04 at 10:35 a.m. EDT on October 1, 2026, while market capitalization stood at USD 1,078.3 billion and the 52-week range was USD 783.85 to USD 1,292.65.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Company stock.